Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion
This article was originally published in The Pink Sheet Daily
Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.
You may also be interested in...
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.